TrialSignal transduction and targeted therapy2024

Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.

Huaqing Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.